NDA 219155 · Leo Pharma As
Anzupgo
Delgocitinib · Topical · Janus Kinase Inhibitor
NovelCDER novel approval, Jul 23, 2025: To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 23, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
22
7 Phase 3, 4 recruiting
FAERS reports
269
85 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2026.
ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. Limitations of Use Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ANZUPGO is a Janus kinase (JAK) inhibitor indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. ( 1 ) Limitations of Use: Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended. ( 1 )
Mechanism: Delgocitinib, a Janus kinase (JAK) inhibitor, inhibits the activity of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). JAK signaling involves recruitment of signal transducers and activators of transcription (STATs) to cytokine receptors, and activation and subsequent localization of STATs to the nucleus, leading to the expression of cytokine-responsive genes to induce specific biological responses in target cells. The exact mechanism of action of delgocitinib in the treatment of moderate to severe CHE is currently not known.
Therapeutic areas: Oncology · Immunology and inflammation · Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ANZUPGO · DELGOCITINIB 2% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Delgocitinib" as an intervention, any sponsor and status, largest first.
- Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 TrialsPivotal-lookingCompleted
LEO PharmaIndustry
NCT04949841 · 801 participants · Start Aug 23, 2021 · Primary completion Sep 18, 2023
Drug: Delgocitinib · For: Chronic Hand Eczema
Sites: Brussels, Belgium; Ghent, Belgium; Kortrijk, Belgium · 95 sites in all
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen SclerosusPivotal-lookingRecruiting
LEO PharmaIndustry
NCT07335588 · 552 participants (planned) · Start May 1, 2026 · Primary completion Mar 10, 2028
Drug: Delgocitinib; Cream Vehicle · For: Lichen Sclerosus
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 35 sites in all
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand EczemaPivotal-lookingCompleted
LEO PharmaIndustry
NCT05259722 · 513 participants · Start Jun 15, 2022 · Primary completion Nov 8, 2023
Drug: Delgocitinib; Toctino · For: Chronic Hand Eczema
Sites: Graz, Austria; Linz, Austria; Calgary, Canada · 102 sites in all
- Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand EczemaPivotal-lookingCompleted
LEO PharmaIndustry
NCT04871711 · 487 participants · Start May 10, 2021 · Primary completion Oct 31, 2022
Drug: Delgocitinib cream; Cream vehicle · For: Chronic Hand Eczema
Sites: Calgary, Canada; Edmonton, Canada; Red Deer, Canada · 54 sites in all
- Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)Pivotal-lookingCompleted
LEO PharmaIndustry
NCT04872101 · 473 participants · Start May 25, 2021 · Primary completion Dec 27, 2022
Drug: Delgocitinib cream; Cream vehicle · For: Chronic Hand Eczema
Sites: Brussels, Belgium; Edegem, Belgium; Ghent, Belgium · 50 sites in all
- A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand EczemaPivotal-lookingCompleted
LEO PharmaIndustry
NCT06004050 · 362 participants · Start Sep 5, 2023 · Primary completion Dec 16, 2024
Drug: Delgocitinib · For: Chronic Hand Eczema
Sites: Beijing, China; Changchun, China; Changsha, China · 37 sites in all
- Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand EczemaPivotal-lookingCompleted
LEO PharmaIndustry
NCT03683719 · 258 participants · Start Nov 28, 2018 · Primary completion Mar 6, 2020
Drug: Delgocitinib cream; Delgocitinib cream vehicle · For: Chronic Hand Eczema
Sites: Tucson, Arizona; Hialeah, Florida; Portland, Oregon · 28 sites in all
- Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.Pivotal-lookingCompleted
LEO PharmaIndustry
NCT03725722 · 251 participants · Start Dec 28, 2018 · Primary completion May 19, 2020
Drug: Delgocitinib cream; Delgocitinib cream vehicle · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Encino, California; Los Angeles, California · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use in unapproved indication58
- pruritus30
- dermatitis atopic25
- drug ineffective22
- dermatitis21
- erythema20
- rash17
- burning sensation13
- dry skin13
- eczema13
- skin burning sensation10
- skin exfoliation10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 7 |
| 2023 | 8 |
| 2024 | 14 |
| 2025 | 89 |
| 2026 | 145 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
Bissonnette R, Warren RB, Pinter A, et al. · Lancet 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Clin Exp Allergy 2024 · Systematic Review, Network Meta-Analysis
- Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
Giménez-Arnau AM, Pinter A, Sondermann W, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.
Gooderham M, Molin S, Bissonnette R, et al. · J Am Acad Dermatol 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Leo Pharma As
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.